Meiyang Innovation Technology officially established its presence in China and formed its first engineering team in June 2022. The company is backed by a top-tier scientific team comprising experts from five countries: China, the United Kingdom, the United States, Australia, and Canada. Its core founding members hail from world-renowned institutions such as University College London, the Massachusetts Institute of Technology, the University of Melbourne, Peking University, Tsinghua University, and The Hong Kong Polytechnic University. Possessing profound academic expertise, extensive industry experience, and exceptional innovative capabilities, the team’s professional domains span clinical medicine, biomedical engineering, aerospace-precision instrument manufacturing and design, artificial intelligence algorithm development, and big data analytics. Dedicated to the deep integration of artificial intelligence with precision intelligent manufacturing, Meiyang Innovation Technology is developing high-end, innovative medical robots equipped with self-observation, judgment, and evolutionary capabilities, ushering in a new era of silicon-based transformation for the RMB 28 trillion market focused on facial, postural, and functional rejuvenation. Meiyang Innovation Technology has secured hundreds of millions of yuan in investment from prominent institutions, including Boyuan Capital, Fosun Group (Fujian Capital), Sinowood Capital, China East Ventures, Jinding Capital, Guoju Venture Capital, Guangzhou Industrial Investment Holdings, Walian Securities, and Nanfang Meigu. Additionally, the company has been awarded government talent incentives valued at tens of millions of yuan. Meiyang Innovation Technology’s Superconducting Microjet 1.0, designed for deep skin wrinkle reduction and the treatment of various pathological conditions affecting the skin and ocular surface, has successfully obtained certification from the U.S. Food and Drug Administration (FDA), earning high recognition from authoritative international institutions. This achievement fully demonstrates Meiyang Technology’s exceptional R&D capabilities and innovative accomplishments in the fields of intelligent anti-aging robots and novel medical robots, laying a solid foundation for Meiyang Innovation Technology’s layout and development in the international market. Building on this success, Meiyang Innovation Technology will further actively implement its internationalization strategy, rapidly expand into global markets, strengthen cooperation with international medical enterprises, and jointly promote product innovation in medical technology. In terms of technological innovation, Meiyang Innovation Technology will continue its rapid R&D efforts while actively expanding its global market presence. The company is committed to exploring the in-depth application of cutting-edge technologies, such as artificial intelligence and robotics, within the youth-oriented industry, striving to launch more innovative and groundbreaking products that set new trends in industry development. In terms of global expansion, Meiyang Technology has demonstrated exceptional international vision and strategic foresight. Its business footprint spans London (UK), Ontario (Canada), Boston (US), as well as Hong Kong, Guangzhou, Beijing, Hangzhou, and Suzhou in China, establishing a complete industrial chain from R&D and manufacturing to sales, while building an extensive and efficient global business network. This highly internationalized presence not only enables Meiyang Innovation Technology to introduce its advanced medical products to global markets and meet the needs of customers in different regions, but also allows it to stay abreast of the latest developments and market trends in the global medtech industry, thereby providing strong support for continuous product R&D and innovation. The successful FDA clearance of Meiyang Innovation Technology’s Superconducting Microjet 1.0 marks a significant milestone in the company’s development and represents a crucial step toward center stage in the global medical technology arena. Looking ahead, Meiyang Innovation Technology will continue to leverage its robust competitive advantages to accelerate its global strategic layout and further expand its international market presence.
